Robert Azelby Sells 4,157 Shares of Juno Therapeutics Inc (JUNO) Stock

Juno Therapeutics Inc (NASDAQ:JUNO) EVP Robert Azelby sold 4,157 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $85.55, for a total transaction of $355,631.35. Following the transaction, the executive vice president now directly owns 89,614 shares of the company’s stock, valued at $7,666,477.70. The sale was disclosed in a document filed with the SEC, which is available through this link.

Robert Azelby also recently made the following trade(s):

  • On Thursday, February 8th, Robert Azelby sold 3,497 shares of Juno Therapeutics stock. The stock was sold at an average price of $85.77, for a total transaction of $299,937.69.
  • On Thursday, February 1st, Robert Azelby sold 4,167 shares of Juno Therapeutics stock. The stock was sold at an average price of $85.78, for a total transaction of $357,445.26.
  • On Monday, January 22nd, Robert Azelby sold 102,539 shares of Juno Therapeutics stock. The stock was sold at an average price of $86.25, for a total transaction of $8,843,988.75.
  • On Wednesday, January 17th, Robert Azelby sold 29,131 shares of Juno Therapeutics stock. The stock was sold at an average price of $68.61, for a total transaction of $1,998,677.91.
  • On Monday, December 18th, Robert Azelby sold 1,816 shares of Juno Therapeutics stock. The stock was sold at an average price of $44.96, for a total transaction of $81,647.36.

Shares of Juno Therapeutics Inc (NASDAQ JUNO) opened at $85.45 on Friday. Juno Therapeutics Inc has a 12 month low of $19.62 and a 12 month high of $86.28. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Juno Therapeutics by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock valued at $187,879,000 after buying an additional 131,864 shares during the period. Capital International Investors purchased a new stake in shares of Juno Therapeutics during the 3rd quarter valued at $256,339,000. BlackRock Inc. grew its stake in shares of Juno Therapeutics by 6.6% during the 4th quarter. BlackRock Inc. now owns 4,834,370 shares of the biopharmaceutical company’s stock valued at $220,981,000 after buying an additional 299,586 shares during the period. State Street Corp grew its stake in shares of Juno Therapeutics by 7.4% during the 2nd quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock valued at $96,742,000 after buying an additional 222,754 shares during the period. Finally, Orbimed Advisors LLC grew its stake in shares of Juno Therapeutics by 123.1% during the 3rd quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock valued at $91,587,000 after buying an additional 1,126,400 shares during the period. 68.90% of the stock is owned by institutional investors.

A number of research analysts have recently weighed in on the stock. Standpoint Research reissued a “hold” rating on shares of Juno Therapeutics in a research note on Wednesday, January 24th. Barclays cut shares of Juno Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $55.00 to $87.00 in a research note on Wednesday, January 24th. Leerink Swann cut shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating and lifted their target price for the stock from $56.00 to $87.00 in a research note on Tuesday, January 23rd. Raymond James Financial cut shares of Juno Therapeutics from an “outperform” rating to a “hold” rating in a research note on Tuesday, January 23rd. Finally, SunTrust Banks reaffirmed a “hold” rating on shares of Juno Therapeutics in a research note on Monday, January 22nd. Two research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and three have issued a buy rating to the stock. Juno Therapeutics has a consensus rating of “Hold” and a consensus price target of $51.20.

COPYRIGHT VIOLATION NOTICE: “Robert Azelby Sells 4,157 Shares of Juno Therapeutics Inc (JUNO) Stock” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.thelincolnianonline.com/2018/02/16/robert-azelby-sells-4157-shares-of-juno-therapeutics-inc-juno-stock.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply